The content on this site is intended for healthcare professionals only
Dr Benedikt Westphalen speaks to ecancer about the concept of pan-tumour therapeutics.
He explains the concept of precision oncology, highlighting that nowadays, personalised treatment is largely based on genomic biomarkers.
Dr Westphalen further talks about the use of pembrolizumab in dMMR/MSI and TMB-high cancers.
NTRK fusions are found in diverse cancer histologies but at a very low frequency mostly. There are drugs that are now available to target these fusions on cancers where their frequency is clinically meaningful.
In conclusion, the landscape of molecular insights and molecular-guided therapeutics is rapidly evolving and post-approval data collection is key to understanding long-term efficacy and safety across cancers.
Burden and trends of breast cancer worldwide: Opportunities for prevention?
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Durable responses in aRCC, how do we optimise treatment?
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
EAU 2024: Bladder cancer latest
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
